<DOC>
	<DOCNO>NCT00130897</DOCNO>
	<brief_summary>The primary objective protocol provide access SU011248 treatment patient metastatic RCC ineligible participation ongoing SU011248 clinical study potential derive clinical benefit treatment SU011248 base judgment investigator .</brief_summary>
	<brief_title>Treatment Use Study With Sunitinib ( SU011248 ) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>Given Expanded Access study meet definition control clinical investigation , , consider applicable drug clinical trial per NIH , Basic Results study require report . Protocol A6181037 identify Expanded Access trial , register ClinicalTrials.gov , however Basic Results post .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>renal cell carcinoma amendable standard therapy curative intent current treatment another therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>